ReNAgade has built a platform combining proprietary delivery technologies, including novel lipid nanoparticles (LNPs), with a broad array of coding, editing, and gene insertion tools in an all‑RNA system. The company aims to address limitations in RNA therapeutics by enabling delivery of RNA medicines to tissues and cells previously inaccessible, substantially expanding the potential addressable disease market. ReNAgade has an established joint venture with Orna Therapeutics that pairs ReNAgade’s delivery platform with Orna’s circular RNA technology; Orna subsequently entered a collaboration with Merck that includes technologies developed under the JV. Founded by MPM BioImpact and based in Cambridge, Mass., ReNAgade assembled a leadership team led by CEO Amit D. Munshi and including CSO Pete Smith, COO Ciaran Lawlor, and CBO Brian Shuster. The leadership team collectively cites deep translational expertise in RNA modalities and the article references their collective contributions to 25 NDAs and 200 INDs. The company launched with a $300 million Series A financing to accelerate development of its RNA delivery platforms and therapeutic programs.

Total raised

$300M

Funding rounds

1

Latest round

Series A

Latest activity

May 2023